These 20 women are 2018's Fiercest in the life sciences industry.
Read 2018's Fiercest Women in Life Sciences report!
The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson & Johnson’s Richard Mason.
The short seller launched the assault after seeing shares in Proteostasis rise 200% in three months.
ShangPharma Innovation is growing its life science incubator on the West Coast as it looks to help early-stage biomedical work get off the ground.
Artificial intelligence company twoXAR says first-round financing will also help it build its pipeline and recruit new staff.
The IPO will equip Alzheon to take its reworking of a once-failed beta amyloid drug into a pivotal trial in a subset of Alzheimer’s patients.
Arbor Biotechnologies has emerged from the shadows with $15.6 million in funding and a CRISPR enzyme that targets RNA.
Ideaya expects to get its first synthetic lethality and immuno-oncology assets into human testing in the first half of next year.
Foghorn seeks to unravel chromatin regulation and develop drugs to correct problems with it.
Perceptive leads a Series B round that will fund Crinetics' CRN00808 candidate through proof-of-concept studies.
European VC firm Forbion, New Science Ventures and BioGeneration Ventures have helped bump up a $19 million series B round for Escalier Biosciences.